The ever-changing nature of SARS-CoV-2 has highlighted the need for high-quality, rapid full genome sequencing. The CEVT Viral Genomics and Surveillance Lab uses Illumina platforms (MiSeq, NextSeq, and NovaSeq) to achieve a balance of rapidity and cost-effectiveness for SARS-CoV-2 full genome sequencing. The CEVT remains the top submitter of viral sequences from the state of Louisiana. The CEVT has partnered with local hospitals for sequencing of COVID-19 positive specimens and vaccine breakthrough cases. CEVT recently successfully competed for and was awarded two-year contract with Louisiana Department of Health for SARS-CoV-2 sequencing beginning in July 2021.For more information on LSU Health Shreveport’s sequencing program, please contact Dr. Krista Queen (, Director of the Viral Genomics and Surveillance Lab.

CEVT Viral Genomics and Sequencing Lab